SCHEMBL12929438

SCHEMBL12929438

CCOC(=O)c1cnc(-c2ccccc2Cl)nc1NC

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 6/20 0.60
▸ KDM4E B2RXH2 2/20 0.60
▸ MAPT P10636 8/20 0.49
▸ SMN1; SMN2 Q16637 3/20 0.49
▸ MAPK1 P28482 3/20 0.49
▸ LMNA P02545 2/20 0.49
▸ ATM Q13315 1/20 0.49
▸ NPC1 O15118 2/20 0.48
▸ HPGD P15428 2/20 0.48
▸ HSD17B10 Q99714 2/20 0.48
▸ TP53 P04637 3/20 0.48
▸ RAB9A P51151 1/20 0.48
▸ FOS P01100 3/20 0.48
▸ JUN P05412 3/20 0.48
▸ NFKB1 P19838 3/20 0.48
▸ NFKB2 Q00653 3/20 0.48
▸ RELA Q04206 3/20 0.48
▸ CYP1A2 P05177 5/20 0.47
▸ POLB P06746 3/20 0.47
▸ MEN1 O00255 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12929448 0.88 ALDH1A1 (0.56) ALDH1A1KDM4EMAPTSMN1; SMN2MAPK1
SCHEMBL12929619 0.87 ALDH1A1 (0.71) ALDH1A1KDM4EMAPTSMN1; SMN2MAPK1
SCHEMBL12929381 0.86 NPSR1 (0.58) ALDH1A1KDM4EMAPTSMN1; SMN2MAPK1
SCHEMBL12929695 0.85 ALDH1A1 (0.53) ALDH1A1KDM4EMAPTSMN1; SMN2MAPK1
SCHEMBL12929573 0.83 ALDH1A1 (0.70) ALDH1A1KDM4EMAPTSMN1; SMN2MAPK1
SCHEMBL5914410 0.83 ALDH1A1 (0.70) ALDH1A1KDM4EMAPTSMN1; SMN2MAPK1
SCHEMBL12929671 0.81 ALDH1A1 (0.71) ALDH1A1KDM4EMAPTSMN1; SMN2MAPK1
SCHEMBL12929741 0.81 FOS (0.66) ALDH1A1KDM4EMAPTSMN1; SMN2MAPK1
SCHEMBL12929462 0.81 ALDH1A1 (0.58) ALDH1A1KDM4EMAPTSMN1; SMN2MAPK1
SCHEMBL12929474 0.80 LMNA (0.51) ALDH1A1KDM4EMAPTSMN1; SMN2MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8324220-B2 Pyrimidines useful as modulators of voltage-gated ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-12-04 — — US disclosed
US-8324220-B2 Pyrimidines useful as modulators of voltage-gated ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-12-04 — — US disclosed
US-20110003814-A1 PYRIMIDINES USEFUL AS MODULATORS OF VOLTAGE-GATED ION CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-01-06 — — US disclosed
US-20110003814-A1 PYRIMIDINES USEFUL AS MODULATORS OF VOLTAGE-GATED ION CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-01-06 — — US disclosed
US-7816529-B2 Pyrimidines useful as modulators of voltage-gated ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-10-19 — — US disclosed
US-7816529-B2 Pyrimidines useful as modulators of voltage-gated ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-10-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003814-A1 PYRIMIDINES USEFUL AS MODULATORS OF VOLTAGE-GATED ION CHANNELS KCNJ1, KCNJ11, TRPV1 ALDH1A1 2361/4885KDM4E 1948/4885MAPT 2103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback